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HIV can be partially contained by host immunity and understanding the basis of this may inform 
vaccine design. The importance of B-cell function in long-term control is poorly understood. 
one method of investigating this is in vivo cellular depletion. In this study, we take advantage 
of a unique opportunity to investigate the role of B cells in an HIV-infected patient. The HIV-1 +   
patient studied here was not taking antiretroviral drugs and was treated for pre-existing low-
grade lymphoplasmacytoid lymphoma by depletion of CD20 +  B cells using rituximab. We 
demonstrate that B-cell depletion results in a decline in autologous neutralizing antibody (nAb) 
responses and a 1.7 log10 rise in HIV-1 plasma viral load (pVL). The recovery of nAbs results in 
a decline in pVL. The HIV-1 sequences diversify and nAb-resistant mutants are subsequently 
selected. These data suggest that B-cell function can contribute to the long-term control of pVL, 
and that nAbs may be more important in controlling chronic HIV-1 infection than previously 
suspected. 
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H
IV-1 is readily able to evade host defence and establish per-
sistent infection. The virus may, however, be partially con-
tained by host adaptive immunity, including both B- and   
T-cell responses. There is good evidence that CD8 +  T-cell responses 
have a role in viral suppression. For example, there are strong HLA 
class I associations with clinical outcome1, and in the SIV model, 
macaques in whom CD8 +  T cells are depleted show significant 
increases in their viral load2. These findings have led to a major ini-
tiative to develop T-cell-based vaccines, and much work to define 
the correlates of protection based on assays of T-cell function3,4. 
However, as a leading HIV vaccine candidate failed to induce pro-
tective T-cell responses5 and recent trial data suggest partial protec-
tion from a vaccine including a gp120 component6, the incentive to 
understand the role of neutralizing antibodies (NAbs) and of B cells 
in HIV infection has increased considerably7–9.
B cells have a multifaceted role in humoral and cellular responses 
to HIV-1, yet their impact in containing the virus remains unclear. 
This is partly because of the complex nature of the antigenic target 
(gp120)10. Key obstacles to the development of both T- and B-cell 
defence are the abilities of the HIV-1 genome to integrate and also 
evolve rapidly in the face of immune selection pressure: the latter 
feature results from both the high replication rate of the virus and 
the error-prone nature of the HIV-1 reverse transcriptase, which 
lacks proofreading capacity11. These mutations are readily accom-
modated within gp120 because of plasticity of the structure and 
the capacity to acquire glycosylation sequons that provide a ‘glycan 
shield’12. Therefore, emerging NAbs repeatedly select mutant viruses 
that are resistant to neutralization13. The NAb response also evolves 
through somatic recombination and affinity maturation of prolif-
erating B cells, but is only partially effective against concurrently   
circulating viruses, while retaining potent activity against strains 
previously circulating within the patient13–15. Such data have cast 
doubt on the contribution of NAbs to the control of virus load, 
despite the counterargument that NAbs must inhibit virus replica-
tion to drive the selection of resistant variants.
Monoclonal  antibodies  have  been  identified  that  both  cross-
  recognize and potently neutralize a variety of HIV-1 strains16–19. The 
targets for these are well defined and include, among others, CD4 and 
co-receptor binding sites and epitopes within the gp41 fusion subunit20. 
These areas are under some structural constraint compared with other 
epitopes, such as in the exposed variable loops. Few potent monoclonal 
antibodies have been isolated, yet the proportion of gp120-specific anti-
bodies capable of neutralization may be greater than once believed8,21. 
Recent studies indicate that some individuals possess NAbs that exhibit 
broad  and  potent  neutralization  capacity18,21,22,  but  functional  data 
to causally link such antibodies to the control of viremia are lacking. 
Furthermore, the contribution of B-cell responses to the containment 
of plasma viral load (pVL) has been difficult to determine, because 
of other important factors that limit virus replication, such as T-cell 
response, virus fitness and host genetics23.
Historically, functional importance has been confidently attrib-
uted to specific arms of the immune response by means of experi-
ments that deplete or transfer that effector arm. Although such data 
are readily available in animal models, they are rarely available in 
humans. As recent vaccine studies have highlighted substantial dif-
ferences between SIV models and HIV, it is important to seek such 
evidence in human studies.
Rituximab (Rituxan, MabThera; Roche) is a monoclonal anti-
body  targeting  CD20  antigen  expressed  on  most  B  cells,  with 
the exception of the terminally differentiated plasma cells. It has 
become widely used for treatment of lymphoma and also of anti-
body-mediated autoimmune diseases24. We report a unique case 
in which rituximab monotherapy was used in a patient with stable 
viraemia, in the absence of antiretroviral therapy (ART).
By  combined  analyses  of  viral  dynamics,  viral  evolution  and 
autologous  NAb  responses,  we  show  reversible  loss  of  HIV-1   
control following rituximab monotherapy. Loss of control was associ-
ated with reduction in titres of NAbs targeting the CD4 binding site, as 
well as with an increase in genetic diversity and transient reversion to 
NAb-sensitive virus. As NAb levels later increased, pVL was once more 
controlled and this was accompanied by further immune selection of 
NAb-resistant viruses. These data suggest that despite ongoing immune 
escape, NAbs secreted by CD20 +  B cells may have a significant role 
in control of pVL during chronic HIV-1 infection, a finding of signifi-
cance for HIV-1 immunotherapies and vaccines.
Results
Clinical  course  of  the  study  subject.  The  patient,  a  Caucasian 
man, was diagnosed with HIV seroconversion illness at the age 
of 58 years. Three years earlier, he was diagnosed with low-grade 
lymphoplasmacytoid  lymphoma,  for  which  he  did  not  receive 
treatment25. Histologically, this was defined as a small lymphocytic 
B-cell  lymphoma  with  plasmacytoid  differentiation  mostly 
expressing CD20 and CD79. The tumour was IgM secreting. His 
only other medical history of note was an acute hepatitis B infection 
approximately 30 years earlier. Following HIV-1 seroconversion, 
the  patient  was  recruited  into  a  prospective,  non-randomized 
observational study of early treatment and received 3 months of 
highly active antiretroviral therapy26. After 30 months, he developed 
a rising paraproteinaemia, attributed to his lymphoma, and received 
thalidomide treatment without clinical effect. He initiated rituximab 
therapy  1,075  days  after  HIV  seroconversion  and  received  four 
weekly doses (375 mg m − 2). He felt unwell 20 weeks after the first dose 
of rituximab with malaise and fever associated with a marked rise 
in HIV pVL (increase of 1.7 log10; Fig. 1). In addition, he developed 
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Figure 1 | Autologous neutralizing antibody titres over time. (a) 
Pseudotyped virus particles were constructed using full-length envelope 
clones that represent majority quasi-species at 336 or 1,042 days after 
seroconversion. Plasma VL over time is indicated (red line). The brief dip 
in viral load over the first 100 days represents the period of initial ART 
as part of the short-course ART trial (shaded grey). The neutralizing 
effects (%; right y axis) of patient sera are shown for autologous viruses 
constructed with cloned env genes derived 336 days (black squares) and 
1,042 days (crosses) after seroconversion. Results from a single clone 
(tested in triplicate) representative of three clones are shown. serum was 
sampled sequentially before and after rituximab therapy (1,075–1,106 days, 
shaded grey), and assayed at concentrations ranging from 1:20 to 1:4,370; 
the neutralizing effects of sera diluted 1:180 are shown here. Error bars 
show standard deviations of triplicate tests. (b) CD4 T lymphocyte count 
(dashed line) is shown over time.ARTICLE     
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biochemical  hepatitis  (attributed  to  reactivation  of  hepatitis  B) 
that resolved with only supportive treatment. Antiretrovirals were 
initiated 1,392 days after seroconversion.
Impact of B-cell depletion on NAb titres. Following rituximab ther-
apy, the subject’s HIV-1 pVL, previously stable, increased by more than 
1.7 log10, peaking at 737,400 copies per ml 4 months after the final dose 
of rituximab (Fig. 1). The pVL subsequently returned to baseline levels 
in the absence of ART. We therefore analysed the impact of rituximab 
therapy on NAb titres in relation to viral dynamics.
Rituximab therapy led to a 30% reduction in total IgG levels, 
which reached their lowest point at the peak of virus load (10.8 g l − 1; 
normal range 8–16 g l − 1) and returned to pre-rituximab levels there-
after (Supplementary Table S1). To evaluate NAb activity throughout 
this period, we generated pseudoviruses derived from autologous 
envelope (env) sequences. Serum obtained before the first dose of 
rituximab potently neutralized virus pseudotyped with autologous 
envelope derived from plasma acquired 2 years previously (day 336 
after seroconversion) (Table 1). The same serum neutralized con-
temporaneous autologous Env pseudotypes, although to a lesser 
extent, with 1:60 serum dilutions effectively blocking more than 
90% infection. Heterologous NAb activity was also observed against 
HXB2 and 8/12 Tier 2/3 clade-B reference strains (NIH, AIDS) 
(Table  2).  Following  rituximab  therapy,  we  observed  a  marked 
decrease in neutralizing activity characterized by a drop of more 
than threefold in IC50 serum titres against day 336 Env pseudotypes, 
which recovered over a 4-month period. Strikingly, these changes 
coincided with the increase in pVL. Recovery of NAb responses cor-
related with control of viraemia (Fig. 1).
Analysis  of  sequence  evolution  in  HIV-1  envelope  over  time. 
To  evaluate  sequence  evolution  over  this  period,  env  products 
were generated by reverse transcription (RT)–PCR from plasma 
viral RNA, before and after rituximab therapy (days 1,075–1,392;   
Fig. 2a). We identified clear sequence diversification as the virus 
peaked during rituximab treatment (mean genetic distance = 0.02 
versus  0.004;  P < 0.0001).  This  diversification  manifested  as  an 
increase in effective population size as measured using BEAST27 
(fivefold change; Fig. 2b). To assess whether these diverse strains 
represented a re-emergence of archived provirus, we used an identi-
cal sequencing strategy to analyse stored peripheral blood mononu-
clear cell (PBMC) samples available from the time of seroconversion 
up to day 1,042; these sequences were placed on a time-structured 
tree  (Supplementary  Fig.  S1).  Viruses  detected  after  rituximab 
treatment did not represent re-emergence of early archived strains; 
those strains present as pVL peaked were most closely related to 
strains present in plasma at day 1,042, with a subset related to those 
archived in PBMC at day 1,042.
Immune selection and neutralization of HIV-1 envelope. The appar-
ent in vivo impact of the NAbs in this individual prompted a search 
for the targets of binding. To identify potential NAb targets, we first 
analysed immune selection using CODEML, analysing the ratio of 
non-synonymous to synonymous mutations (dN/dS) at each site. We 
observed two sites under selection (Fig. 3; Supplementary Fig. S1)—
position 339 (dN/dS = 7.6, P < 0.0001) and position 363 (dN/dS = 6.977, 
P = 0.03).  Residue  363  lies  between  the  β14  and  β15  anti-parallel 
strands of gp120 and is exposed on the surface of the outer domain in 
close proximity to the CD4 binding loop28. Computational modelling 
of atomic level envelope structures has shown that mutations proxi-
mal to the CD4-binding loop are critical in conferring resistance to 
CD4bs antibodies29. Furthermore, site-directed mutagenesis of site 363   
has previously been shown to affect neutralization of the CD4bs anti-
bodies M-14 and b1230,31. Before the first dose of rituximab (day 1,042 
after seroconversion), position 363 was occupied by an arginine in all 
viral RNA sequences, whereas all proviral DNA clones sampled up to 
and including day 1,042 had a glutamine at the same position. Fol-
lowing rituximab therapy, R363 variants were temporarily replaced 
with Q363 variants, which reverted to arginine residues as NAb titres 
rebounded and viraemia was controlled.
Before rituximab therapy, an asparagine at site 339 formed part 
of an N-linked glycosylation site. This residue is located within the 
α3 helix, which is exposed on the surface of the protein according 
to atomic level structures. A previous study showed that site 339 is 
involved in recognition by 2G12, a monoclonal antibody the bind-
ing of which is carbohydrate dependent32. However, in addition to 
this, mutations at site 339 have been reported to affect binding by 
monoclonal antibody b12: this effect is observed despite site 339 
being some distance away from the CD4 binding site, and poten-
tially occurs through conformational perturbation32. No other sites 
in the envelope were found to be under positive selection, indicating 
that mutations at these positions affected NAb binding.
To  examine  the  effect  of  sequence  changes  on  neutralization 
susceptibility, pseudoviruses mimicking Q363R and R339N/E were 
constructed by site-directed mutagenesis. The selected Q363/339E 
mutation reduced the IC50 titres of day 1,042 serum by more than 
twofold (IC50 from  > 775 to 300). Confirming previous data, the 
Q363R mutation was also shown to inhibit neutralization by fivefold 
by antibody b1231, whereas N339E inhibited neutralization suscepti-
bility by fourfold to the carbohydrate-specific antibody 2G1212,32.
To further define the site of binding of the patient’s NAbs, we 
performed  a  direct  competition  experiment  using  well-defined 
monoclonal antibodies and recombinant clade B envelope as the 
antigenic target (Fig. 4). This experiment showed strong binding 
competition between patient sera and antibodies b12, 4.8d (which 
targets an epitope overlapping with the co-receptor binding site) and 
447-52D (which targets the V3 loop). No competition was observed 
against 2G12. The experiment also revealed a clear decline in com-
petition for binding in samples taken during the peak of viraemia, 
which recovered as pVL declined, in good accordance with the data 
obtained from the neutralization experiments, but using an inde-
pendent system of evaluation (Fig. 4b).
Table 1 | IC50 neutralizing titres against autologous viruses.
Serum (day) D336 pseudovirus D1042 pseudovirus HXB2 VSV-G
1,042  > 775 150 850  < 20
1,135  > 775 225 1000 n/T
1,239 220  < 120* 875 20
1,295 250 150 325 20
1,308 360 375 1000  < 20
1,353 600 425 3950 n/T
negative serum  < 20  < 20  < 20 n/T
Abbreviations: n/T, virus-serum combinations that were not tested because of limited availability of sera; VsV-G, vesicular stomatitis virus control.
The mean half maximal inhibitory concentrations of sera (IC50, reciprocal dilutions) are given for three viruses pseudotyped with representative Env clones derived from d336 and d1042 plasma  
(autologous).
*1:120 was the highest concentration of day 1,239 serum that could be tested against day 1,042 virus due to limited serum availability.ARTICLE
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Analysis of other potential effects of rituximab. We investigated 
other possible causes for the observations made, particularly the 
possibility of an indirect impact on cellular immunity33. We ana-
lysed the sequence of key CTL epitopes over time, and carried out 
interferon-γ (IFN-γ) ELISpot analyses. Although some mutations in 
pre-rituximab sequences were observed, the majority of the epitopes 
remained stable (Table 3). It is of importance that control over pVL 
was regained without further escape/reversion at these sites.
Second,  immune  activation  through  recrudescence  of  other 
infectious agents may have a role in this case. Concurrent with the 
pVL increase, the patient also developed elevated liver transami-
nases, associated with reactivation of previously controlled hepatitis 
B virus (HBV) infection34. However, control of HIV was observed 
at a time when HBV load was still high, suggesting that HBV rep-
lication per se was not driving HIV replication (up to day 1,389; 
Supplementary  Fig.  S2)  in  this  patient.  In  the  setting  of  acute   
illness, there was no evidence of EBV, HHV-6, HHV-8 or HCV 
in blood. Cytomegalovirus was present only at low copy number   
(50 copies per ml). A bronchoalveolar lavage was tested for a broad 
panel of relevant viruses, all of which were negative, including VZV   
and HSV1/2. Clearly, these data do not exclude reactivation of a 
further  latent  infection,  or  concurrent  superinfection,  although   
the major herpesvirus infections appear unlikely to be contributing 
significantly.
Discussion
In this study, B-cell depletion led to a decline in NAb titres against 
HIV, concurrent with rising pVL. Recovery of NAb titres coincided 
with control over viral load. Multiple analytical techniques were 
used to longitudinally characterize the distinct virus population that 
emerged as NAbs returned. The common ancestor of this new virus 
population was defined by polymorphisms at two residues exposed 
on the surface of the virus envelope, both of which showed evidence 
of positive selection, with mutations affecting binding of NAbs.
There are no published studies on the impact of rituximab alone 
on HIV viraemia in humans. Studies on acute SIVmac infection in 
macaques treated with rituximab indicate a role for NAb responses 
in containing post-acute viral load35,36. In contrast, a recent study 
Table 2 | IC50 neutralizing titres against heterologous viruses.
Serum (day) HXB2 6535 QH0692 PVO TRO AC10.0 pREJO 4541 pTRJO 4551
pRHPA 
4259
1,042 850 220 220 90 120 90 140 50 50
1,353 3950 300 170 90 130 160 220 140 120
negative  < 20 20*  < 20  < 20  < 20  < 20 20* 20*  < 20
The mean half-maximal inhibitory concentrations of sera (IC50, reciprocal dilutions) are given for pseudoviruses derived  from a standardized reference panel (nIAID, nIH) (heterologous). Reductions in 
infected TZm-bl cells by pooled HIV-negative sera (*) were attributed to cellular toxicity which was not observed at concentrations below 1:20.
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Figure 2 | Diversification of HIV-1 env sequences after rituximab 
therapy. (a) A time-structured tree, showing divergence-time estimates 
among intra-host plasma HIV-1 clonal sequences before and after 
rituximab therapy (shaded grey), based on a Bayesian relaxed molecular 
clock applied to 969 nucleotides58. The external nodes represent 
sequences taken from time points indicated by the colours given in the 
figure key (inset). The topology is of the highest likelihood calculated 
using BEAsT, with branch lengths proportional to time estimates for the 
subtending nodes (summarizing 60 million markov chain monte Carlo 
(mCmC) simulations, generated after discarding 6 million as burn-in). 
All the parameters in the mCmC started from random values, except for 
substitution rates and population size, where the priors were imported 
from the combined proviral and plasma viral sequence data of the same 
host calculated by BEAsT software. (b) The effective population sizes 
(neτ) were calculated using BEAsT. The x axis (days after seroconversion) 
is the same as for Figure 2a59.
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Figure 3 | Tracking of selected envelope mutants. This figure shows 
the relative frequencies of polymorphisms at sites (a) 339, dN/dS = 7.61 
P < 0.0001 and (b) 363 dN/dS = 6.98 P < 0.031. The individual bars along 
the x axis represent the different time points of sequencing (comparable 
to Fig. 2; supplementary Fig. s1): these are taken either from proviral DnA 
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The time of rituximab therapy is indicated. Each bar shows the frequency 
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residues detected.ARTICLE     

nATuRE CommunICATIons | DoI: 10.1038/ncomms1100
nATuRE CommunICATIons | 1:102 | DoI: 10.1038/ncomms1100 | www.nature.com/naturecommunications
© 2010 Macmillan Publishers Limited. All rights reserved.
using African Green monkeys did not reveal any effect of rituximab 
treatment during acute SIVagm infection37; thus, data from human 
studies are important to resolve this issue.
It is possible that depletion of B cells had an indirect impact on 
viral load through modulation of CD4 +  or CD8 +  T-cell subsets. 
Although we cannot exclude this, the mechanism for such an indi-
rect effect is not clear and, importantly, no impact on CD8 +  T-cell 
responses has been observed in the SIV models quoted above36. The 
delay of several weeks that is observed between rituximab treat-
ment and the change in viral load is much more consistent with 
the observed decline in antibody titres than a direct B-cell/T-cell 
interaction, which would be expected to take effect immediately. 
In addition, the changes in the prevailing sequence (reversion and 
subsequent re-selection of a mutated NAb epitope; Figs 2, 3; Supple-
mentary Fig. S1) are consistent with relaxation and re-application of 
NAb-mediated selection pressure.
The impact of other reactivating viruses on HIV load is complex. 
As in this case, rituximab treatment is known to have the potential to 
reactivate HBV38, even in those with previously controlled infection 
(HbsAg − , HBcoreAb + ). This points to an important role for B cells 
in long-term control of HBV—a virus in which CD8 +  T cells have 
an important role in acute disease39. The relationship between HBV 
pVL and HIV pVL is not fully understood, but overall these appear 
to be independent40,41. In this case, HBV and HIV pVL increased 
within a similar timeframe; however, control over HIV occurred 
spontaneously, whereas HBV load remained high, indicating that 
they were differentially regulated in this patient (Supplementary 
Fig. S2). However, this does not exclude a secondary impact of HBV 
through induction of liver inflammation or other consequences of 
immune activation. In addition, although we did not find other evi-
dence of systemic reactivation of other major pathogens in this indi-
vidual, it remains possible that local or low-level reactivation could 
also affect HIV pVL.
Overall, our findings support previous suggestions of an evolution-
ary balance between virus and NAbs12,42. At first sight, these findings 
appear at odds with previous studies that fail to confirm an associa-
tion between long-term virus control and NAb response, especially in 
elite controllers43. However, as shown here, the dynamics of immune 
responses are critical to their interpretation; therefore complex rela-
tionships could easily be missed in cross-sectional studies, especially 
analyses of those with favourable CD8 +  T-cell responses1,43,44.
There is a clear relationship between the changes in NAb titre 
and pVL demonstrated in this study, although the mechanism of 
action of such NAbs in vivo may be complex. Studies using engi-
neered antibodies in which Fc binding was disrupted have shown 
that interactions of NAbs with infected cells, leading to engagement 
of effector cells, may provide an important component of the pro-
tective capacity in vivo45,46. It is also possible that other non-NAb 
specificities not defined using in vitro NAb assays might have a role   
in vivo47. It is noteworthy that as B-cell responses to HIV envelope   
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Figure 4 | Characterization of patient antibodies by competition ELISA. 
(a) serial dilutions of patient serum (x axes) collected on days 1,042 (filled 
diamonds), 1,270 (filled circles), 1,295 (filled triangles) and 1,353 (filled 
squares) after seroconversion reduced gp120 binding with nAbs b12,  
447-52D and 4.8d, thereby reducing colorimetric change and light 
absorption (A450 nm, y axes). Pooled serum collected from HIV-uninfected 
subjects (stars) did not compete with any nAb for gp120 binding. All 
sera failed to compete with 2G12 for gp120 binding. (b) The reciprocal 
dilutions of sera, sampled before and after rituximab therapy, which reduce 
gp120-nAb binding by 50% (IC50, right y axis). Hundred percent binding 
was taken as that observed in microtitre wells containing IgGb12 (empty 
squares), 4.8d (empty triangles) or 447D (empty circles) in the absence of 
patient sera. Corresponding VLs are shown by the red line (left y axis).
Table 3 | Analysis of CD8 +  T cell responses and epitope evolution over time.
Epitope Autologous sequence
Response  
pre-rituximab Year 1
Response  
pre-rituximab Year 3
Mutation  
pre-rituximab
Mutation  
post-rituximab
A11 gag TK8 TLYCVHQK 1,200 — K8n Q7A
A11 pol AK11 ACQGVGGPGHK 300 — — G9A
A11 nef QK10 QVPLRPmTYK — — — —
A11 pol AK9 AIFQCsmTK — — — —
B8 gag p17 GK9 GGsKKYQLK — — K3R/K7Q K3R/K7Q
B8 gag p17 EV9 ELKsLYnTV 160 200 — —
B8 gag p24 DI8 DIYKRWII 640 600 — —
B8 gag p24 DL9 DCKTILKAL — — — —
B8 nef Wm9 WPKVRERm — — K3G/E6D K3R
B8 nef FL8 FLKEKGGL — — K5Q K5Q
B57 gag TW10* TsnLQEQIGW* — — n3T (242)* n3T (242)*
CD8 +  T cell responses were analysed using ex vivo IFn-γ-ELIspot analysis (spot forming units/million PBmCs are shown). The HLA Class IA and Class IB genotypes are A0101, A1101 and B0801, B0801. 
sequencing of the corresponding peptides was carried out at the time points shown, and mutating residues have been underlined.
*This epitope is a B57 escape mutant, transmitted to, but not recognized by the recipient, and which shows reversion pre-rituximab therapy.ARTICLE
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may be poorly sustained, it has been proposed that long-term plasma 
cell pools may not be established (reviewed in refs 48,49). As plasma 
cells are spared the effects of rituximab50 (and total IgG levels there-
fore remain relatively less affected), it is suggested that the antiviral 
NAbs identified here, and potentially elsewhere, are maintained by 
B-cell populations that express CD20.
In conclusion, this unique study suggests that B cells, and their 
secreted NAbs, can affect HIV viral load in chronic infection. This 
evidence, derived directly from observations in man, may inform 
the rational design of future immunotherapies and HIV vaccines.
Methods
Construction of HIV-1 env expression cassettes. The study was approved accord-
ing to local ethical review (IRB Number 99/IA/161E). Full-length virus env was 
PCR amplified from cDNA obtained by RT of plasma-derived viral RNA collected 
336 and 1,042 days after seroconversion for construction of pre-rituximab Env-
pseudotyped virus. The latter time point represented virus present around the time 
of rituximab treatment. The primers used were env1A (outer sense, 5′-CACCG-
GCTTAGGCATCTCCTATGGCAGGAAGAA3′), env1M (outer antisense and 
RT, 5′-TAGCCCTTCCAGTCCCCCCTTTTCTTTTA-3′)51, envF1/2 (inner sense, 
5′-GGGCTCGAGACCGGTGAGCAGAAGACAGTGGCAATG( ± A)-3′) and 
envR1/2 (inner antisense, 5′-AAATCTAGAGGGCCCCCATTGCCACCCATBTTA
( ± TAGC)-3′). Bulk PCR products were restriction-cloned into pcDNA3.1 (Invitro-
gen) using sites ApaI and XhoI to result in pcDNA3.1.env, followed by sequencing. 
Of 20 genetically distinct clones that were most representative of the consensus 
sequence, 3 were selected for neutralization experiments.
Site-directed mutagenesis. Where stated, 100 ng pcDNA3.1.env was used as a  
template for PCR amplification using PfuUltraII Fusion HS (Stratagene) in the  
supplied buffer supplemented with 250 µM dNTPs and 3% dimethylsulphoxide.  
Mutagenesis primers contained restriction sites inserted by synonymous  
mutation (underlined): R339Nf (5′-ATTGTAACATTTCTCGAGTAGAATGGAA 
TGACACCTTAA-3′), R339Nr (5′-TTAAGGTGTCATTCCATTCTACTCGAGAA 
ATGTTACAAT-3′), R339Ef (5′-ATTGTAACATTTCTAGAGTAGAATGGGAAGA 
CACCTTAA-3′), R339Er (5′-TTAAGGTGTCTTCCCATTCTACTCTAGAAATGT 
TACAAT-3′), Q363Rf (5′-TAAAACAATAATCTTTAATCGATCCTCAGGA-3′) 
and Q363Rr (5′-TCCTGAGGATCGATTAAAGATTATTGTTTTA-3′). After 18 
amplification cycles (95 °C for 50 s, 60 °C for 50 s and 68 °C for 9 min), dam-methyl-
ated PCR templates were eliminated by DpnI restriction digestion. Mutant clones 
were identified by restriction analysis and confirmed by nucleotide sequencing. 
Double mutants were constructed by sequential PCR amplifications.
Construction and neutralization of Env-pseudotyped virus particles. Autolo-
gous env clones and a heterologous panel of subtype-B reference strains52 were 
co-transfected with the HIV-1 backbone nl4.3∆env53 into 293T-17 human epithelial 
kidney cells using Lipofectamine 2000 (Invitrogen). At 48 h following transfection, 
supernatants were collected by 0.45-µm filtration and stored at  − 150 °C before ti-
tration onto the HIV-permissive reporter cell line, TZM-bl, which stably expresses 
Escherichia coli β-galactosidase under regulatory control of a Tat-responsive HIV-1 
long terminal repeat. Cells were fixed with glutaraldehyde (0.2%) and stained with 
X-gal substrate 48 h after infection. After staining, infected cells formed ‘blue’ 
focus-forming units, which were counted under light microscopy to determine the 
virus titre. Autologous Env-pseudotyped virus was confirmed to be R5 tropic by 
titration onto CD4 + CCR5 +  and CD4 + CXCR4 +  GHOST cell lines, which express 
green fluorescence protein in response to viral Tat.
For neutralization experiments, pseudotyped virus was incubated for 1 h with 
a threefold dilution series of heat-inactivated serum, or with broadly specific NAbs 
(b12 or 2G12)12. After 48 h, fixed and stained cells were manually counted and 
neutralization was measured as the percentage reduction of focus-forming units 
relative to non-neutralized virus controls. Samples were prepared in triplicate 
microtitre wells and counts were verified by separate investigators (DB and ET).
Competitive binding assays. Antibody specificity was mapped using a com-
petitive-binding enzyme-linked immunosorbent assay (ELISA). High-binding 
microtitre plates (Greiner) were coated overnight with recombinant Bal-strain 
gp120 and blocked with 2% milk powder to limit non-specific antibody binding. 
Each plate received threefold dilution series of patient sera and was incubated with 
50% saturating titres of biotinylated NAbs (b12, 2G12, 447-52D). An additional 
plate was pre-incubated with the CD4 peptide mimic M33 before incubation with 
biotinylated NAb 4.8d54. Bound NAb was detected with streptavidin horseradish 
peroxidase and TMB chromogen substrate. Serum-mediated inhibition of NAb 
binding was determined as the percentage reduction in light absorbance (A450 nm) 
compared with wells that received dilution buffer (PBS 0.05% Tween 20, 1% bovine 
serum albumin) instead of serum.
ELISpot for interferon-γ secreting CD8 +  T cells. This was performed using 
panels containing optimized HLA-matched peptides55. Fresh PBMCs were tested 
for T-cell responses using ex vivo Interferon-γ ELISpot assays. 96-well nitrocel-
lulose plates (Millipore) were coated with 0.05 µg ml − 1 recombinant anti-IFN-γ 
(Mabtech) in PBS overnight at 4 °C. Plates were then washed seven times with PBS 
and blocked with R10 for 2 h at 37 °C. PBMCs (2 × 105) were added to each well and 
then stimulated with peptide. The final concentration for peptide stimulation was 
10 µg ml − 1 and each peptide was tested in duplicate. Medium alone was used as a 
negative control and 1 µg ml − 1 phytohemagglutinin was used as a positive control 
for all assays. The assay plates were incubated for 18 h at 37 °C and, after extensive 
washing with PBS, a biotinylated secondary mouse anti-human IFN-γ monoclonal 
antibody (0.05 µg ml − 1; Mabtech) was added. The plates were developed using an 
alkaline phosphatase-conjugating substrate AP colour reagent A + B (BioRad).  
After 15 min, the colorimetric reaction was stopped by washing with tap water. 
Plates were air dried and spots were counted using an automated ELISpot reader 
(AID ELISpot Reader System). IFN-γ-producing T cells were expressed as spot-
forming units per 1×106 cells. The number of specific IFN-γ-secreting cells was cal-
culated by subtracting the unstimulated control value from the stimulated sample.
Sequence evolution and bioinformatics software. For sequence evaluation in 
evolutionary studies, PCR amplification of HIV env, followed by cloning and 
sequencing, was performed as previously described56. Analyses of evolution and 
site-specific selection were performed using BEAST27 and CODEML57. CODEML 
was used to identify sites that have been subjected to positive selection using site-
specific codon models. These models allow dN/dS to vary among sites, with values 
significantly above 1 indicating sites that had been under positive selection. We 
compared the fit of models M7 (which does not allow any sites to have a dN/dS of 
above 1) with M8 (which fits a class of sites with a dN/dS of above 1), using a likeli-
hood ratio rest. The empirical Bayesian approach implemented by CODEML was 
used to identify codons under positive selection, using a cut-off of  > 90%. BEAST 
was used to model the evolution of the viral sequences through time, using the log-
normal relaxed clock distribution to accommodate rate variation among branches. 
The multiple alignments contained 969 nucleotides. BEAST was run for 60 million 
steps, with the first 10% discarded as burn-in, and convergence was checked using 
Tracer. All analyses were repeated to ensure convergence. A preliminary BEAST 
analysis was performed that included the proviral sequence data, as these samples 
spanned a longer period of time than just the sequences obtained from plasma 
samples. The rate of evolution and effective population size were estimated from 
these time-structured sequences, and used in an analysis including only sequences 
obtained from plasma samples. 
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